Last reviewed · How we verify

Theratechnologies — Portfolio Competitive Intelligence Brief

Theratechnologies (TH) pipeline: 2 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

TH (TSX) 2 marketed 0 filed 2 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Egrifta TESAMORELIN ACETATE marketed Growth Hormone Releasing Factor Analog Growth hormone-releasing hormone receptor Immunology 2010-01-01
Placebo-Control Placebo-Control marketed
Placebo for Tesamorelin Placebo for Tesamorelin phase 3 Clinical Trial Control
TH9507 TH9507 phase 3 Growth hormone analog Growth hormone receptor (GHR) Endocrinology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ANRS, Emerging Infectious Diseases · 1 shared drug class
  2. Ascendis Pharma A/S · 1 shared drug class
  3. Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · 1 shared drug class
  4. Changchun GeneScience Pharmaceutical Co., Ltd. · 1 shared drug class
  5. Dong-A ST Co., Ltd. · 1 shared drug class
  6. National Institute of Allergy and Infectious Diseases (NIAID) · 1 shared drug class
  7. Xiamen Amoytop Biotech Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Theratechnologies:

Cite this brief

Drug Landscape (2026). Theratechnologies — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/theratechnologies. Accessed 2026-05-13.

Related